HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EWG Asks CDC To Add Sunscreen Ingredients To National Biomonitoring Program

Executive Summary

The US Centers for Disease Control and Prevention should “diligently” track systemic exposure to the 12 UV filters currently in question at FDA, the Environmental Working Group says in a recent petition.

You may also be interested in...



Proposed Sunscreen Rule, Final MUsT Guidance Jumpstart Next-Gen UV Filter Discussions

CDER agrees to protect DSMs confidential business information by redacting most correspondence but says general meeting minutes will be made public. To address TEA sponsors' concerns about disclosing proprietary information, "in some situations FDA may hold private meetings with sponsors who request them without subsequently disclosing proprietary information," CDER Division of Nonprescription Drug Products responds to DSM request.

EWG Casts FDA’s Proposed Sunscreen Rule As Validation Of Longstanding Concerns

The Environmental Working Group has long favored mineral over chemical sunscreens in its annual ratings and buying guide, with particular concerns about oxybenzone, one of 12 active ingredients that FDA says need additional safety data to support GRASE determinations.

FDA MUsT Shows Sunscreen Ingredient Absorption ‘Not Just A Theoretical Concern’

In FDA’s maximal usage trial published May 6 in JAMA, oxybenzone, octocrylene, avobenzone and ecamsule all absorbed into subjects’ bloodstreams at levels that raise systemic safety questions. The active ingredients are among 12 that FDA identified in a February proposed rule as currently lacking data to support continued GRASE status.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel